

NON-IONIZING RADIATION, PART 2: RADIOFREQUENCY ELECTROMAGNETIC FIELDS

VOLUME 102

This publication represents the views and expert opinions of an IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, which met in Lyon, 24-31 May 2011

LYON, FRANCE - 2013

IARC MONOGRAPHS
ON THE EVALUATION
OF CARCINOGENIC RISKS
TO HUMANS

CONTENTS

NOTE TO THE READER	1
LIST OF PARTICIPANTS	3
PREAMBLE	9
A. GENERAL PRINCIPLES AND PROCEDURES	9
1. Background	9
2. Objective and scope	10
3. Selection of agents for review	11
4. Data for the <i>Monographs</i>	11
5. Meeting participants	12
6. Working procedures	13
B. SCIENTIFIC REVIEW AND EVALUATION	14
1. Exposure data	15
2. Studies of cancer in humans	16
3. Studies of cancer in experimental animals	20
4. Mechanistic and other relevant data	23
5. Summary	26
6. Evaluation and rationale	27
References	31
GENERAL REMARKS	33
1. EXPOSURE DATA	37
1.1 Introduction	37
1.1.1 Electromagnetic radiation	37
1.1.2 The electromagnetic spectrum	38
1.1.3 Exposures to EMF	38
1.2 Sources of exposure	41
1.2.1 Natural fields	41
1.2.2 Man-made fields	45

1.3	Dosimetry	68
1.3.1	Introduction.....	68
1.3.2	Dosimetric exposure.....	68
1.3.3	Coupling of incident fields with the body.....	71
1.3.4	Dependence on local anatomy.....	73
1.3.5	Estimation of local tissue temperature based on psSAR	74
1.3.6	Dosimetry methods	75
1.3.7	Exposure set-ups for laboratory studies.....	77
1.3.8	Exposure characterization in laboratory studies.....	78
1.3.9	Biological factors in studies in experimental animals.....	79
1.4	Measurement techniques.....	87
1.4.1	Introduction.....	87
1.4.2	Near-field and dosimetric probes.....	87
1.4.3	Measurement antennae	89
1.4.4	Temperature instrumentation	89
1.4.5	Measuring SAR and the near field	91
1.4.6	Incident-field measurements in the far field	91
1.4.7	Broadband measurements.....	92
1.4.8	Calibration	94
1.4.9	Uncertainty assessment.....	94
1.4.10	Specific measurement problems	95
1.5	Interaction of RF-EMF with biological systems.....	97
1.5.1	Thermal effects.....	98
1.5.2	Physiological effects	99
1.5.3	Magnetic-field effects.....	103
1.5.4	Conclusion	104
1.6	Exposure to RF radiation.....	104
1.6.1	Personal exposure	104
1.6.2	Occupational exposure	111
1.6.3	Environmental exposure.....	112
1.7	Exposure guidelines and standards	115
1.7.1	Scientific basis.....	115
1.7.2	Basic restrictions.....	116
1.7.3	Reference levels	117
	References.....	118

2. CANCER IN HUMANS	129
2.1 Occupational exposure	129
2.1.1 Cancer of the brain	130
2.1.2 Leukaemia and lymphoma	147
2.1.3 Uveal (ocular) melanoma	156
2.1.4 Cancer of the testis	156
2.1.5 Other cancers	157
2.2 Environmental exposure from fixed-site transmitters	158
2.2.1 Cancer of the brain	158
2.2.2 Leukaemia and lymphoma	174
2.2.3 Other cancers	186
2.3 Exposure from mobile phones	187
2.3.1 Cancer of the brain	192
2.3.2 Leukaemia and lymphoma	234
2.3.3 Uveal (ocular) melanoma	242
2.3.4 Cancer of the testis	242
2.3.5 Cancers of the parotid gland	249
2.3.6 Other cancers	250
References	251
3. CANCER IN EXPERIMENTAL ANIMALS	257
3.1 Studies of carcinogenicity	257
3.1.1 Mouse	257
3.1.2 Rat	257
3.1.3 Transgenic and tumour-prone models	262
3.2 Initiation–promotion studies	265
3.2.1 Skin-tumour model	265
3.2.2 Lymphoma model	274
3.2.3 Mammary-gland tumour model	274
3.2.4 Brain-tumour model	275
3.3 Co-carcinogenesis	277
References	281

4. OTHER RELEVANT DATA.....	285
4.1 Genetic and related effects	285
4.1.1 Humans	285
4.1.2 Experimental systems: <i>in vivo</i>	290
4.1.3 Experimental systems: <i>in vitro</i>	301
4.2 Effects of low-level exposure to RF radiation on the immune system	329
4.2.1 Immunotropic effects of exposure to RF radiation in humans.....	329
4.2.2 Immunotropic effects of exposure to RF radiation in experimental animals	330
4.2.3 Immunotropic effects of exposure to RF radiation in experimental systems.....	333
4.3 Effects of exposure to RF radiation on gene and protein expression	337
4.3.1 Gene expression.....	377
4.3.2 Protein expression.....	345
4.4 Other relevant effects	360
4.4.1 Humans	360
4.4.2 Experimental systems: <i>in vivo</i>	363
4.4.3 Experimental systems: <i>in vitro</i>	369
4.5 Physical factors that affect interpretation of study results	383
4.5.1 Effects of critical RF-field parameters	383
4.5.2 Frequency dependence and frequency windows	384
4.5.3 Polarization	384
4.5.4 Dose and duration of exposure.....	384
4.5.5 Background fields of extremely low frequency (ELF)	384
4.5.6 Net static geomagnetic field	385
References	385
5. SUMMARY OF DATA REPORTED.....	405
5.1 Exposure data	405
5.2 Human carcinogenicity data	407
5.2.1 Personal use of wireless telephones	407
5.2.2 Occupational exposure	410
5.2.3 Environmental exposure	412
5.3 Animal carcinogenicity data	413
5.4 Other relevant data	414
5.4.1 Genetic and related effects of exposure	414
5.4.2 Reaction of the immune system after exposure	415
5.4.3 Effects on genes, proteins and signalling pathways	416
5.4.4 Other mechanistic end-points.....	416

6. EVALUATION	419
6.1 Cancer in humans	419
6.2 Cancer in experimental animals.....	419
6.3 Overall evaluation.....	419
6.4 Rationale of the evaluation of the epidemiological evidence.....	419
GLOSSARY	421
LIST OF ABBREVIATIONS	427
CUMULATIVE CROSS INDEX TO IARC MONOGRAPHS	429

NOTE TO THE READER

The term ‘carcinogenic risk’ in the *IARC Monographs* series is taken to mean that an agent is capable of causing cancer. The *Monographs* evaluate cancer hazards, despite the historical presence of the word ‘risks’ in the title.

Inclusion of an agent in the *Monographs* does not imply that it is a carcinogen, only that the published data have been examined. Equally, the fact that an agent has not yet been evaluated in a *Monograph* does not mean that it is not carcinogenic. Similarly, identification of cancer sites with *sufficient evidence* or *limited evidence* in humans should not be viewed as precluding the possibility that an agent may cause cancer at other sites.

The evaluations of carcinogenic risk are made by international working groups of independent scientists and are qualitative in nature. No recommendation is given for regulation or legislation.

Anyone who is aware of published data that may alter the evaluation of the carcinogenic risk of an agent to humans is encouraged to make this information available to the Section of IARC Monographs, International Agency for Research on Cancer, 150 cours Albert Thomas, 69372 Lyon Cedex 08, France, in order that the agent may be considered for re-evaluation by a future Working Group.

Although every effort is made to prepare the *Monographs* as accurately as possible, mistakes may occur. Readers are requested to communicate any errors to the Section of IARC Monographs, so that corrections can be reported in future volumes.

